Effects of rosiglitazone on the expressions of MCP-1 and PAI-1 induced by acute phase serum amyloid protein A in endothelial cells

Hu Yun
2007-01-01
Abstract:Objective To observe the effects of acute phase serum amyloid protein A(A-SAA) and rosiglitazone on the gene expressions of monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor type-1 (PAI-1) in endothelial cells. Methods Total RNA of ECV304 endothelial cells incubated with 0.5μg/ml, 5μg/ml A-SAA and rosiglitazone (10μmol/L) for 8 hours or 24 hours was isolated by TRIZOL method. Semi-quantitative RT-PCR was performed to quantitate the expressions of MCP-1 and PAI-1. Results A-SAA significantly induced MCP-1, PAI-1 mRNA expressions in ECV304 endothelial cells (P0.01) in the manners of dose-dependence and time-dependence. PPARg activator rosiglitazone could partly reduce the A-SAA-induced MCP-1 and PAI-1 mRNA expressions. Conclusions A-SAA is a new pro-inflammatory adipokine and has atherogenic effects. A-SAA increases MCP-1, PAI-1 gene expressions, which may contribute to insulin resistance and cardiovascular complications. Rosiglitazone alleviates the A-SAA-induced Monocyte chemotactic protein-1 and PAI-1 expressions, which may be related to improving insulin sensitivity and to decreasing cardiovascular complications.
What problem does this paper attempt to address?